Nicholas Coupe

612 total citations
19 papers, 220 citations indexed

About

Nicholas Coupe is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Nicholas Coupe has authored 19 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Nicholas Coupe's work include Cancer Immunotherapy and Biomarkers (8 papers), Melanoma and MAPK Pathways (5 papers) and CAR-T cell therapy research (3 papers). Nicholas Coupe is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Melanoma and MAPK Pathways (5 papers) and CAR-T cell therapy research (3 papers). Nicholas Coupe collaborates with scholars based in United Kingdom, Australia and United States. Nicholas Coupe's co-authors include Miranda Payne, Laura Spiers, Mark R. Middleton, Pippa Corrie, Avinash Gupta, Weng Ng, Deme Karikios, Leticia Campo, Michael Lin and Shanley Chong and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Nicholas Coupe

18 papers receiving 217 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicholas Coupe United Kingdom 7 139 72 60 43 24 19 220
Mona Amini‐Adlé France 9 178 1.3× 81 1.1× 48 0.8× 25 0.6× 11 0.5× 30 275
Benjamin Y. Lu United States 7 151 1.1× 41 0.6× 69 1.1× 80 1.9× 9 0.4× 15 216
Rohit Thummalapalli United States 8 94 0.7× 78 1.1× 52 0.9× 56 1.3× 21 0.9× 17 192
Camilo Garcia France 3 147 1.1× 57 0.8× 75 1.3× 75 1.7× 29 1.2× 10 238
Lucie Heinzerling Germany 8 146 1.1× 70 1.0× 51 0.8× 52 1.2× 6 0.3× 22 210
Ningning Li China 8 97 0.7× 70 1.0× 35 0.6× 55 1.3× 71 3.0× 27 240
Stefan Schliep Germany 10 103 0.7× 82 1.1× 92 1.5× 24 0.6× 16 0.7× 27 251
Kieran Adam United States 11 195 1.4× 73 1.0× 191 3.2× 37 0.9× 14 0.6× 26 350
Ayman Al‐Habeeb Canada 6 170 1.2× 74 1.0× 120 2.0× 79 1.8× 27 1.1× 7 313
Kristina Buder‐Bakhaya Germany 7 256 1.8× 77 1.1× 106 1.8× 50 1.2× 20 0.8× 10 320

Countries citing papers authored by Nicholas Coupe

Since Specialization
Citations

This map shows the geographic impact of Nicholas Coupe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Coupe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Coupe more than expected).

Fields of papers citing papers by Nicholas Coupe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Coupe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Coupe. The network helps show where Nicholas Coupe may publish in the future.

Co-authorship network of co-authors of Nicholas Coupe

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Coupe. A scholar is included among the top collaborators of Nicholas Coupe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Coupe. Nicholas Coupe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Heist, Rebecca S., Elaine Shum, Esther García Pagès, et al.. (2025). MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.. Journal of Clinical Oncology. 43(16_suppl). 8613–8613. 1 indexed citations
2.
3.
Ye, Weiyu, Chelsea Taylor, Rosalin Cooper, et al.. (2024). Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination. Journal for ImmunoTherapy of Cancer. 12(4). e008151–e008151. 2 indexed citations
4.
Blackhall, Fiona, Adel Samson, K. Franks, et al.. (2023). 1502TiP A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1. Annals of Oncology. 34. S846–S846. 3 indexed citations
5.
Coupe, Nicholas, David J. Pinato, Justin Fairchild, et al.. (2023). IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). 2575–2575. 1 indexed citations
6.
Watson, Robert, Orion Tong, Chelsea Taylor, et al.. (2023). 135P The lymphocyte stability index (LSI) forms a pan-cancer peripheral biomarker for overall survival post initiation of immune checkpoint blockade (ICB). Annals of Oncology. 34. S235–S235. 1 indexed citations
7.
Damato, Valentina, Antonio Berretta, Sudarshini Ramanathan, et al.. (2022). Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors. JAMA Neurology. 79(9). 949–949. 6 indexed citations
8.
Coupe, Nicholas, Esther Bridges, Leticia Campo, et al.. (2022). WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma. Cellular Oncology. 46(2). 391–407. 5 indexed citations
9.
Coupe, Nicholas, Ian Walters, Robert A. Kramer, Uzi Gileadi, & Mark R. Middleton. (2022). A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL).. Journal of Clinical Oncology. 40(16_suppl). 2582–2582. 1 indexed citations
10.
Ye, Weiyu, Anna Olsson‐Brown, Robert Watson, et al.. (2021). Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. British Journal of Cancer. 124(10). 1661–1669. 33 indexed citations
11.
Fane, Mitchell E., Brett L. Ecker, Amanpreet Kaur, et al.. (2020). sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. Clinical Cancer Research. 26(21). 5709–5719. 22 indexed citations
12.
Spiers, Laura, Nicholas Coupe, & Miranda Payne. (2019). Toxicities associated with checkpoint inhibitors—an overview. Lara D. Veeken. 58(Supplement_7). vii7–vii16. 75 indexed citations
13.
Eyre, Toby A., Graham P. Collins, Avinash Gupta, et al.. (2018). A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer. 125(1). 99–108. 16 indexed citations
14.
Coupe, Nicholas, Avinash Gupta, & Simon Lord. (2015). Early phase cancer clinical trials: design, ethics and future directions. British Journal of Hospital Medicine. 76(7). 409–413. 2 indexed citations
15.
Coupe, Nicholas, Pippa Corrie, James Larkin, et al.. (2014). PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. European Journal of Cancer. 51(3). 359–366. 19 indexed citations
16.
Coupe, Nicholas, Pippa Corrie, James Larkin, et al.. (2014). A Phase 1, Dose Escalation Study of Paclitaxel with Gsk1120212 (Trametinib) for the Treatment of Advanced Melanoma. Annals of Oncology. 25. iv379–iv379. 1 indexed citations
17.
Coupe, Nicholas, Keith Cox, Katherine Clark, Michael Boyer, & Martin R. Stockler. (2013). Outcomes of Permanent Peritoneal Ports for the Management of Recurrent Malignant Ascites. Journal of Palliative Medicine. 16(8). 938–940. 11 indexed citations
18.
Coupe, Nicholas, Deme Karikios, Shanley Chong, et al.. (2013). Metabolic information on staging FDG-PET–CT as a prognostic tool in the evaluation of 97 patients with gastric cancer. Annals of Nuclear Medicine. 28(2). 128–135. 19 indexed citations
19.
Coupe, Nicholas, Judith Lacey, & Christine Sanderson. (2012). Unique Manifestations of Catecholamine Release in Malignant Pheochromocytoma: An Experience Within an Inpatient Palliative Care Unit. Journal of Pain and Symptom Management. 43(5). 967–972. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mona Amini‐Adlé Breakdown of academic impact, for papers by Benjamin Y. Lu Breakdown of academic impact, for papers by Rohit Thummalapalli Breakdown of academic impact, for papers by Camilo Garcia Breakdown of academic impact, for papers by Lucie Heinzerling Breakdown of academic impact, for papers by Ningning Li Breakdown of academic impact, for papers by Stefan Schliep Breakdown of academic impact, for papers by Kieran Adam Breakdown of academic impact, for papers by Ayman Al‐Habeeb Breakdown of academic impact, for papers by Kristina Buder‐Bakhaya
Rankless by CCL
2026